Sujana Movva is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 343 publications with 4,993 citations (h-index 27); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1275 York Ave
New York, NY 100656007
Telephone
646-888-4342Registry record last updated 14 Feb 2019.
Clinical trials
- A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
Sponsor: Memorial Sloan Kettering Cancer Center
- Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Deciphera Pharmaceuticals Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
40.9%Kinase inhibitor40.9%Imatinib Mesylate66%Qinlock18%Sunitinib Malate16%Part D<11 patientsMetabolism & gastrointestinal
31.5%Serotonin-3 Receptor Antagonist18.2%Ondansetron Hcl100%Part D≥17 patientsProton pump inhibitor7.2%Pantoprazole Sodium100%Part D<11 patients+ 1 more class in this area
Sensory organs
12.7%Corticosteroid12.7%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma
Clinical Cancer Research
2024 - Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma
Clinical Cancer Research
2024 - A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Clinical Cancer Research
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”